Brad Verret was biochemist and former medical student who was employed at The Dow Chemical Company in polymer characterization. He served on our general advisory board. Brad’s benzodiazepine injury from Xanax began in 2011 as an undergraduate student. His health began to decline and he developed neurological symptoms consistent with multiple sclerosis. In 2014, Brad became aware of his benzodiazepine dependence the resulting harm to his health, leading to being rapidly tapered off the drug in a week. After suffering four agonizing months from the rapid withdrawal, he was reinstated and slowly tapered off Valium for a year, which was completed in August 2016. Brad enjoyed using his free time to share his experience, strength, and hope with those impacted by iatrogenic illness. Brad passed away in 2017

Hidden Dangers of Fluoroquinolone Antibiotics in the Benzodiazepine-Dependent Population
Whether it was for a sinus infection or bronchitis, most people have taken an antibiotic at some point in their lives. Antibiotics can be lifesaving medications but, like all other drugs, they come with risks. In particular, one specific class of antibiotic drugs called the fluoroquinolones carry serious risks that few people are aware of. […]
www.benzoinfo.com
Psychopharmacology and Commonly Encountered Enzymatic Drug-Drug Interactions: Implications on Psychiatric Treatment and Psychopharmaceutical Discontinuation Protocols
It’s no surprise that drugs don’t always play together nicely in the human body. The term “drug interaction” can stir up a great deal of fear in unsuspecting healthcare consumers and, as a result, a number of web-based drug interaction cross checking systems have been made available to help spread awareness of the risks of combining […]
www.benzoinfo.com